The association between MAP3K mutations and worse clinical outcomes retained statistical significance after adjustment for patient menopausal status, primary tumor size (pT), nodal involvement at diagnosis (pN), tumor grade and the percentage of Ki-67 labelling index (adjusted HR for DRFS: 3.29, 95%CI = 1.46–7.42, p-value = 0.0039 and adjusted HR for OS: 5.46, 95%CI = 2.19–13.60, p-value = 0.0002 respectively, see Fig 3C and 3D). Here, MKI67 is linked to neoplasm.